l 687414 has been researched along with olanzapine in 1 studies
| Studies (l 687414) | Trials (l 687414) | Recent Studies (post-2010) (l 687414) | Studies (olanzapine) | Trials (olanzapine) | Recent Studies (post-2010) (olanzapine) |
|---|---|---|---|---|---|
| 13 | 0 | 4 | 6,339 | 1,340 | 2,383 |
| Protein | Taxonomy | l 687414 (IC50) | olanzapine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.097 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.155 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.047 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.04 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.541 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.768 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.118 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.047 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.421 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.531 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.392 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.072 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.173 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.092 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.038 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.021 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.047 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 1.033 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.013 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.078 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.057 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.013 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.158 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.2028 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bradaia, A; Bruns, A; Buchy, D; Chaboz, S; Galley, G; Groebke Zbinden, K; Hoener, MC; Kilduff, TS; Metzler, V; Morairty, SR; Moreau, JL; Mory, R; Norcross, RD; Pouzet, B; Revel, FG; Risterucci, C; Tuerck, D; Wallace, TL; Wettstein, JG | 1 |
1 other study(ies) available for l 687414 and olanzapine
| Article | Year |
|---|---|
A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Attention; Benzodiazepines; Body Weight; Cocaine; Conditioning, Operant; Depression; Disease Models, Animal; Dopamine Uptake Inhibitors; Electroencephalography; Hallucinogens; Haloperidol; Humans; Macaca fascicularis; Magnetic Resonance Imaging; Male; Mental Recall; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microinjections; Motor Activity; Mutation; Olanzapine; Oocytes; Oxazoles; Phencyclidine; Phenethylamines; Protein Binding; Pyrrolidinones; Rats; Rats, Wistar; Receptors, G-Protein-Coupled; Reinforcement, Psychology; Schizophrenia; Swimming; Telemetry; Tritium; Xenopus | 2013 |